Cara Therapeutics Inc. announced that it has filed a registration statement on Form S-1 with the US Securities and Exchange Commission (SEC). The filing was related to the proposed initial public offering (IPO) of the company's common stock, the statement said.

However, the number of Cara shares to be offered and the price range for the offering has yet to be disclosed.  

Cara Therapeutics Inc. is a biopharmaceutical company based in Shelton, Connecticut. The company specializes in developing and commercializing new chemical entities to treat human diseases. It has raised a funding total of USD38.7 million since it was established, according to figures compiled by CrunchBase.

Financial services holding company Stifel Financial Corp. and investment bank and asset management firm Piper Jaffray will be acting as joint bookrunners. Canaccord Genuity, Needham & Company and Janney Montgomery Scott will be acting as co-managers, the statement said.